NSE: GRANULES | BSE: 532482

Strong Performer, Getting Expensive

Download real time

875.50 5.10 (0.59%)

New 52W High in past week

1.2M NSE+BSE Volume

NSE 18 Sep, 2026 3:31 PM (IST)

21,694.6

Market Cap

High in industry

Beta 1Year

Low volatility

Granules India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GRANULES, BSE:532482 Granules India Ltd.

Search Inside the pdf :

Granules India Ltd.

23 Jul 2026

875.50

0.59%

Complex Generics Driving Structural Margin Expansion

Accumulate: Granules India Ltd.

Target

Deven Choksey

Granules India enters FY27 with multiple growth catalysts aligned, including the anticipated USFDA resolution for the Gagillapur facility, continued ramp-up of the Genome Valley formulation plant, and increasing contribution from complex generics.

Granules has gained 50.30% in the last 6 Months

Granules India Ltd.

22 Jul 2026

875.50

0.59%

Granules India

Buy: Granules India Ltd.

Target

ICICI Direct

About the stock: Granules is a large-scale vertically integrated company that manufactures API, intermediates and finished dosages. It owns eight manufacturing facilities catering mainly for export markets (~94% of sales). In April 2025, it acquired Senn Chemicals AG, a Swiss CDMO specializing in peptide...

Granules India Ltd. is trading above all available SMAs

Granules India Ltd.

22 Jul 2026

875.50

0.59%

Strong margin print; on the right trajectory

Buy: Granules India Ltd.

Target

Emkay

Granules’s 1QFY27 EBITDA/PAT were ahead of our estimates (by 7%/11%), primarily on the back of a beat in gross margin. The gross margin (65.6%) beat was aided by a favorable mix, while the quarter’s EBITDA margin outperformance has also come in the face of elevated R&D spend.

Number of FII/FPI investors increased from 241 to 302 in Jun 2026 qtr.

Granules India Ltd.

21 Jul 2026

875.50

0.59%

FDF/API drive earnings

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered in-line revenue/EBITDA/PAT in 1QFY27. Higher formulation (FDF) and API sales sustained growth momentum in 1QFY27 as well.

Granules has gained 61.12% in the last 1 Year

Granules India Ltd.

09 Jul 2026

875.50

0.59%

Granules India Ltd. – Q1FY27 Preview:

Hold: Granules India Ltd.

Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 13.7% / 13.7% / 14.3% for the period of FY26-FY28.

Granules has gained 61.12% in the last 1 Year

Granules India Ltd.

15 May 2026

875.50

0.59%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

over or under performance to benchmark index Granules India Ltd. (Inc.) is a vertically integrated, high growth pharmaceutical company headquartered in Hyderabad, India. The company manufactures Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates...

Granules India Ltd. is trading above all available SMAs

Granules India Ltd.

02 May 2026

875.50

0.59%

Margin-Led Growth Anchored by Complex Generics and CDMO Expansion

Accumulate: Granules India Ltd.

Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 13.4% / 13.3% / 13.7% for the period of FY26-FY28.

Granules India Ltd. has an average target of 964.00 from 5 brokers.

Granules India Ltd.

29 Apr 2026

875.50

0.59%

FDF/API/CDMO drive earnings

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered in-line revenue and higher-than-expected EBITDA/PAT (6% beat) for the quarter. Higher formulation (FDF) and API sales led to improvement in overall momentum for the quarter.

Granules India Ltd. has an average target of 964.00 from 5 brokers.

Granules India Ltd.

20 Apr 2026, 12:00AM

875.50

0.59%

Granules India

Buy: Granules India Ltd.

Target

ICICI Direct

Granules has gained 61.12% in the last 1 Year

Granules India Ltd.

31 Mar 2026

875.50

0.59%

Underappreciated US model; multiple optionalities in play

Buy: Granules India Ltd.

Target

Emkay

We initiate coverage of Granules with BUY and SOTP-based Mar-27 TP of Rs800 (implied target EV/EBITDA of ~12x; ~30% upside). Granules fits into our framework of backing companies with a smaller US base + a US portfolio construct with strong near-term growth visibility.

Granules India Ltd. is trading above all available SMAs

Is Granules India Ltd. worth buying?

873 Votes:

Buy 84.19%

Sell 10.08%

Hold 5.73%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf